Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability

Annals of Neurology

Volumn 46, Issue 5, 1999, Pages 747-754

  Van Waesberghe, J H T M ^a   Kamphorst, W ^a   De Groot, C J A ^a   Van Walderveen, M A A ^a   Castelijns, J A ^a   Ravid, R ^b   Lycklama A Nijeholt G J ^a   Van Der Valk, P ^a   Polman, C H ^a   Thompson, A J ^c   Barkhof, F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS BRAIN BANK   (Netherlands)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MYELIN;

ADULT; AGED; ARTICLE; AUTOPSY; CELL DENSITY; CELL LOSS; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTIPLE SCLEROSIS; MYELINATION; NERVE FIBER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SCORING SYSTEM;

EID: 0032724612     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(199911)46:5<747::AID-ANA10>3.0.CO;2-4     Document Type: Article

References (23)

1. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary-progressive multiple sclerosis. Lancet 1998;352:1491-1497
2. McDonald WI, Miller DH, Thompson AJ. Are magnetic resonance findings predictive of clinical outcome in multiple sclerosis? The dilemma of interferon-β. Ann Neurol 1994;36: 14-18
3. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996;39:6-16
4. Barkhof F, Filippi M. Can MR be a predictor of long-term clinical outcome for MS? Int MS J 1995;2:4-9
5. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338: 278-285
6. Arnold DL, Matthews PM, Francis G, Antel J. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn Reson Med 1990;14:154-159
7. van Hecke P, Marchal G, Johannik K, et al. Human brain proton localized NMR spectroscopy in multiple sclerosis. Magn Reson Med 1991;18:199-206
8. 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry 1997;63:736-742
9. van Walderveen MAA, Barkhof F, Hommes OR, et al. Correlating MR imaging and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short TR/short TE ("T1-weighted") spin-echo images. Neurology 1995;45:1684-1690
10. Truyen L, van Waesberghe JHTM, Barkhof F, et al. Accumulation of hypointense lesions ("black holes") on T1-weighted images of multiple sclerosis patients correlates with disease progression in secondary progressive MS patients. Neurology 1996; 47:1468-1476
11. Gass A, Barker GJ, Kidd D, et al. Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann Neurol 1994;36:62-67
12. Brück W, Bitsch A, Kolenda H, et al. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997;42:783-793
13. 1-weighted spin-echo MR in multiple sclerosis. Neurology 1998;50:1282-1288
14. Berry I, Barker G, Barkhof F, et al. A multi-centre measurement of magnetization transfer ratio in normal white matter. J Magn Reson Imaging 1999;9:441-446
15. De Groot CJA, Ruuls SR, Theeuwes JWM, et al. Immunocytochemical characterization of the expression of inducible and constitutive isoforms of nitric oxide synthase in demyelinating multiple sclerosis lesions. J Neuropathol Exp Neurol 1997;56: 10-20
16. van Waesberghe JHTM, Castelijns JA, Scheltens P, et al. Comparison of four potential MR parameters for severe tissue destruction in multiple sclerosis. Magn Reson Imaging 1997;15: 155-162
17. de Groot CJA, Montagne L, Barten AD, et al. Expression of transforming growth factor (TGF)-β1, -β2 and -β3 isoforms and TGF-β type I and type II receptors in multiple sclerosis lesions and adult astrocyte cultures. J Neuropathol Exp Neurol 1999;58:174-187
18. Lucchinetti CF, Brück W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 1996;6:259-274
19. Bö L, Mork S, Kong PA, et al. Detection of MHC class II-antigens on macrophages and microglia, but not on astrocytes and endothelia in active multiple sclerosis lesions. J Neuroimmunol 1994;51:135-146
20. Miller DH, Grossmann RI, Reingold SC, McFarland HF. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998;121:3-24
21. Dousset V, Brochet B, Vital A, et al. Lysolecithin-induced demyelination in primates: preliminary in vivo study with MR and magnetization transfer. Am J Neuroradiol 1995;16: 225-231
22. Barnes D, Munro PMG, Youl D, et al. The longstanding MS lesion: a quantitative MR and electron microscopy study. Brain 1991;114:1271-1280
23. Ferguson B, Maryszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997;120:393-399